After hinting COVID-19 drug Pemgarda might not work against new strains, the FDA announced the medication is effective against KP.3.1.1, the dominant variant. 

Johnson & Johnson will discontinue upfront 340B drug rebates for certain hospitals, raising concerns among healthcare providers and advocacy groups. The proposed policy, set to take effect Oct. 15, would prevent certain hospitals from accessing 340B discounts for Stelara, used…

A recent study highlighted the use of MRIs in reducing overdiagnosis in prostate cancer screening. 

A recent study suggests that semaglutide, typically used for Type 2 diabetes, may significantly reduce the risk of opioid overdoses in patients with opioid use disorder, according to research published Sept. 25 by JAMA Network.

The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating schizophrenia in decades, Medscape reported Sept.…

Pfizer has announced the withdrawal of all lots of Oxbryta, its drug for sickle cell disease, amid concerns about increased complications and fatal events. 

Large companies can save millions of dollars by addressing one common misconception about health insurance plans, according to billionaire entrepreneur Mark Cuban. 

The FDA is reassessing the approval of immune checkpoint inhibitors for treating advanced HER2-negative gastric adenocarcinoma, questioning their broad application regardless of patients' PD-L1 expression levels. 

A recent study from Harvard Medical School introduced TxGNN, an innovative AI tool designed to identify potential drug candidates for over 17,000 rare and neglected diseases. 

Sen. Bernie Sanders highlighted a potential shift in the pricing of Ozempic during a Senate Health, Education, Labor and Pensions Committee hearing Sept. 24, during which three major pharmacy benefit managers said they would increase coverage if Novo Nordisk lowered…